Publications

Nature reviews. Cancer

Reflecting on 25 years of cancer research: transformative advances and unmet expectations.

08-09-2026

Nature aging

Turning CDK4/6 inhibitors against the dark side of senescence.

01-09-2026

Cell chemical biology

XPO1 inhibition induces NCOR1-Dependent oxidative stress to suppress hepatocellular carcinoma.

20-08-2026

Cancer discovery

A Counterintuitive Approach to Cancer Therapy.

03-08-2026

Trends in immunology

Exploiting immunogenic cell death to promote antitumor immunity.

01-08-2026

The FEBS journal

Inhibition of mitochondrial protein translation sensitizes tumor cells to death receptor 5 agonistic antibody.

29-07-2026

Cancer cell

Targeting tumor-intrinsic STK40 induces immune vulnerability and drives T cell reinvigoration.

13-07-2026

European journal of cancer (Oxford, England : 1990)

The SHERPA trial: A phase I study combining SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 in patients with KRAS-mutant pancreatic, non-small cell lung and colorectal cancer.

18-06-2026

Clinical cancer research : an official journal of the American Association for Cancer Research

PI3K Inhibition in Combination with Tamoxifen in Patients with Metastatic HR+/HER2- Breast Cancer: Clinical and Circulating Tumor DNA Results.

15-05-2026

Nature protocols

Inducible CRISPR-Cas9 screening platform to interrogate non-proliferative cellular states.

01-05-2026

Cell

CLIM-TIME links genetic cancer drivers to immune landscapes.

05-03-2026

Journal of experimental & clinical cancer research : CR

CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic cancer.

22-01-2026

ESMO open

Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial.

01-12-2025

Nature cancer

European cancer research requires renewed urgency.

01-12-2025

Proceedings of the National Academy of Sciences of the United States of America

CRISPR screens identify the ATPase VCP as a druggable therapeutic vulnerability in cholangiocarcinoma.

30-09-2025

Molecular oncology

A single gene mutation predicts response to immune checkpoint blockade in ovarian clear cell carcinoma.

01-09-2025

Trends in cancer

Prospects for understanding and exploiting the consequences of hyperactivation lethality.

01-07-2025

Proceedings of the National Academy of Sciences of the United States of America

Reply to Mishima et al.: MALT1 modulates GPX4 expression by regulating its stability.

20-05-2025

Developmental cell

DYRK1A-TGF-β signaling axis determines sensitivity to OXPHOS inhibition in hepatocellular carcinoma.

19-05-2025

Cell death and differentiation

Senolysis by ABT-263 is associated with inherent apoptotic dependence of cancer cells derived from the non-senescent state.

01-05-2025

The Journal of pathology

Afadin loss induces breast cancer metastasis through destabilisation of E-cadherin to F-actin linkage.

01-05-2025

Cell death and differentiation

Apoptotic priming in senescence predicts specific senolysis by quantitative analysis of mitochondrial dependencies.

01-05-2025

Gut

Perturbation of mRNA splicing in liver cancer: insights, opportunities and challenges.

07-04-2025

Signal transduction and targeted therapy

Hepatocellular carcinoma: signaling pathways and therapeutic advances.

07-02-2025

Proceedings of the National Academy of Sciences of the United States of America

Deciphering the role of the MALT1-RC3H1 axis in regulating GPX4 protein stability.

07-01-2025

Proceedings of the National Academy of Sciences of the United States of America

An antibiotic that mediates immune destruction of senescent cancer cells.

24-12-2024

Cancer cell

Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy.

09-12-2024

Signal transduction and targeted therapy

Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: a prospective, single-arm exploratory trial.

09-12-2024

Nature reviews. Cancer

Cancer drug-tolerant persister cells: from biological questions to clinical opportunities.

01-10-2024

Molecular oncology

A combination of protein phosphatase 2A inhibition and checkpoint immunotherapy: a perfect storm.

01-10-2024

Clinical cancer research : an official journal of the American Association for Cancer Research

A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma.

01-08-2024

Cancer discovery

Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy.

01-07-2024

Cancer cell

The case for therapeutic overactivation of oncogenic signaling as a potential cancer treatment strategy.

10-06-2024

Gastroenterology

Dual Inhibition of CDK4/6 and XPO1 Induces Senescence With Acquired Vulnerability to CRBN-Based PROTAC Drugs.

01-06-2024

EMBO reports

The phosphatase inhibitor LB-100 creates neoantigens in colon cancer cells through perturbation of mRNA splicing.

01-05-2024

Cell

Embracing cancer complexity: Hallmarks of systemic disease.

28-03-2024

Cell reports. Medicine

Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse.

19-03-2024

Proceedings of the National Academy of Sciences of the United States of America

Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS-mutant cancers.

27-02-2024

Cancer cell

Precision treatment in advanced hepatocellular carcinoma.

12-02-2024

Cell research

LICOB: a powerful organoid platform for drug discovery.

01-01-2024

BJR open

How to 19F MRI: applications, technique, and getting started.

13-11-2023

Molecular oncology

Molecular Oncology and the EACR: new partners in communicating and supporting cancer research.

01-06-2023

Molecular oncology

Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma.

01-06-2023

Clinical and translational medicine

Drug-drug synthetic lethality to combat cancer: From bench to bedside.

01-05-2023

Angiogenesis

Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy.

01-05-2023

Nature reviews. Gastroenterology & hepatology

Evolving therapeutic landscape of advanced hepatocellular carcinoma.

01-04-2023

Molecular oncology

More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics.

01-03-2023

Nature reviews. Drug discovery

Rational combinations of targeted cancer therapies: background, advances and challenges.

01-03-2023

Nature cancer

A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF^V600E colorectal tumors.

01-02-2023

EBioMedicine

Sustained activation of EGFR-ERK1/2 signaling limits the response to tigecycline-induced mitochondrial respiratory deficiency in liver cancer.

01-01-2023

Reflecting on 25 years of cancer research: transformative advances and unmet expectations.

Turning CDK4/6 inhibitors against the dark side of senescence.

XPO1 inhibition induces NCOR1-Dependent oxidative stress to suppress hepatocellular carcinoma.

A Counterintuitive Approach to Cancer Therapy.

Exploiting immunogenic cell death to promote antitumor immunity.

Inhibition of mitochondrial protein translation sensitizes tumor cells to death receptor 5 agonistic antibody.

Targeting tumor-intrinsic STK40 induces immune vulnerability and drives T cell reinvigoration.

The SHERPA trial: A phase I study combining SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 in patients with KRAS-mutant pancreatic, non-small cell lung and colorectal cancer.

PI3K Inhibition in Combination with Tamoxifen in Patients with Metastatic HR+/HER2- Breast Cancer: Clinical and Circulating Tumor DNA Results.

Inducible CRISPR-Cas9 screening platform to interrogate non-proliferative cellular states.

CLIM-TIME links genetic cancer drivers to immune landscapes.

CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic cancer.

Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial.

European cancer research requires renewed urgency.

CRISPR screens identify the ATPase VCP as a druggable therapeutic vulnerability in cholangiocarcinoma.

A single gene mutation predicts response to immune checkpoint blockade in ovarian clear cell carcinoma.

Prospects for understanding and exploiting the consequences of hyperactivation lethality.

Reply to Mishima et al.: MALT1 modulates GPX4 expression by regulating its stability.

DYRK1A-TGF-β signaling axis determines sensitivity to OXPHOS inhibition in hepatocellular carcinoma.

Senolysis by ABT-263 is associated with inherent apoptotic dependence of cancer cells derived from the non-senescent state.

Afadin loss induces breast cancer metastasis through destabilisation of E-cadherin to F-actin linkage.

Apoptotic priming in senescence predicts specific senolysis by quantitative analysis of mitochondrial dependencies.

Perturbation of mRNA splicing in liver cancer: insights, opportunities and challenges.

Hepatocellular carcinoma: signaling pathways and therapeutic advances.

Deciphering the role of the MALT1-RC3H1 axis in regulating GPX4 protein stability.

An antibiotic that mediates immune destruction of senescent cancer cells.

Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy.

Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: a prospective, single-arm exploratory trial.

Cancer drug-tolerant persister cells: from biological questions to clinical opportunities.

A combination of protein phosphatase 2A inhibition and checkpoint immunotherapy: a perfect storm.

A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma.

Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy.

The case for therapeutic overactivation of oncogenic signaling as a potential cancer treatment strategy.

Dual Inhibition of CDK4/6 and XPO1 Induces Senescence With Acquired Vulnerability to CRBN-Based PROTAC Drugs.

The phosphatase inhibitor LB-100 creates neoantigens in colon cancer cells through perturbation of mRNA splicing.

Embracing cancer complexity: Hallmarks of systemic disease.

Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse.

Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS-mutant cancers.

Precision treatment in advanced hepatocellular carcinoma.

LICOB: a powerful organoid platform for drug discovery.

How to 19F MRI: applications, technique, and getting started.

Molecular Oncology and the EACR: new partners in communicating and supporting cancer research.

Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma.

Drug-drug synthetic lethality to combat cancer: From bench to bedside.

Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy.

Evolving therapeutic landscape of advanced hepatocellular carcinoma.

More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics.

Rational combinations of targeted cancer therapies: background, advances and challenges.

A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors.

Sustained activation of EGFR-ERK1/2 signaling limits the response to tigecycline-induced mitochondrial respiratory deficiency in liver cancer.

This site uses cookies

A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF^V600E colorectal tumors.